Showing results (21-30 of 85) with videos related to
Sort By:
Pageof 9
Acta Ophthalmologica Scandinavica. Supplement|February 11, 1999
Blue-yellow perimetry in patients with ocular hypertoneA Serra, I Zucca, A Tanda, et al.Acta Ophthalmologica Scandinavica. Supplement|February 11, 1999
The nerve fibre layer in ocular hypertension. Preliminary resultsM Marraffa, S Perfetti, R Morbio, et al.Acta Ophthalmologica Scandinavica. Supplement|January 1, 1996
A syndrome with retinitis pigmentosa, progressive hearing impairment, vestibular dysfunction, and congenital cataractT Rosenberg, A ParvingActa Ophthalmologica Scandinavica. Supplement|November 1, 2000
Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarateA J AguilarActa Ophthalmologica Scandinavica. Supplement|March 10, 2001
Ocular hypertension: 12 years' follow-upJ Pecori Giraldi, A Repossi, G De Benedetti, et al.Acta Ophthalmologica Scandinavica. Supplement|March 10, 2001
Experimental ocular acute hypertension-induced chromatinic alterations in astrocytic cells in rat optic nerveN Pescosolido, G Scarsella, G Risuleo, et al.Acta Ophthalmologica Scandinavica. Supplement|May 25, 1999
Comparison of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic conjunctivitisM Discepola, J Deschenes, M AbelsonActa Ophthalmologica Scandinavica. Supplement|May 25, 1999
Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge modelJ Deschenes, M Discepola, M AbelsonActa Ophthalmologica Scandinavica. Supplement|May 25, 1999
The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge modelM B Abelson, R Q LanierActa Ophthalmologica Scandinavica. Supplement|February 11, 1999
Effects of brimonidine 0.2% on blue-yellow perimetry of glaucomatous patientsL Mastropasqua, M Ciancaglini, P Carpineto, et al.Pageof 9